scholarly journals Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients—A Nationwide Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2087
Author(s):  
Eerik E. E. Santala ◽  
Miia Artama ◽  
Eero Pukkala ◽  
Kala Visvanathan ◽  
Synnöve Staff ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Use ◽  
Risk Analysis ◽  
Ace Inhibitors ◽  
Population Based ◽  
Competing Risk ◽  
Competing Risk Analysis ◽  
Time Period ◽  
Morbidity Risk

Ovarian cancer (OC) has a poor prognosis. Hypertension may be a prognostic factor for OC, but it is unclear whether antihypertensive (anti-HT) drug use of modifies OC prognosis. We performed a population-based analysis assessing the effect of anti-HT drug use on OC mortality. A cohort of 12,122 women identified from the Finnish Cancer Registry with OC in 1995–2013 was combined with information on their anti-HT drug use during the same time period. Use of each anti-HT drug was analysed as a time-dependent variable. Analyses were run for five, ten and full follow-up (19-year) mortality with cardiovascular morbidity risk evaluated in competing risk analysis. No anti-HT drug group was associated with OC survival within five years after OC diagnosis. At ten years, a dose-dependent association was observed between pre-diagnostic ACE-inhibitor use and improved OC survival. With full follow-up, post-diagnostic high-intensity use associated with reduced OC death risk for multiple anti-HT drug groups. In competing risk analysis, only the post-diagnostic use of ACE-inhibitors associated with increased OC survival. Anti-HT drugs were not associated with survival benefits within five years after OC diagnosis. ACE-inhibitors may confer survival benefits in women with OC, but further confirmatory studies are needed.

scholarly journals Risk Factors for Amputation After Revascularisation for Critical Limb Ischemia – A Competing Risk Analysis of a Population Based Cohort.

2019 ◽  
Vol 58 (6) ◽  
pp. e467-e468
Author(s):  
Eva Torbjörnsson ◽  
Lena Blomgren ◽  
Carin Ottosson ◽  
Ann-Mari Fagerdahl ◽  
Lennart Boström ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Analysis ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Population Based ◽  
Competing Risk ◽  
Competing Risk Analysis

Risk of dementia and death in patients with atrial fibrillation: A competing risk analysis of a population-based cohort

2016 ◽  
Vol 220 ◽  
pp. 440-444 ◽  
Author(s):  
Irene Marzona ◽  
Marta Baviera ◽  
Tommaso Vannini ◽  
Mauro Tettamanti ◽  
Laura Cortesi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Risk Analysis ◽  
Population Based ◽  
Competing Risk ◽  
Competing Risk Analysis

scholarly journals Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Rafael Abós-Herràndiz ◽  
Teresa Rodriguez-Blanco ◽  
Isabel Garcia-Allas ◽  
Isabel-Magdalena Rosell-Murphy ◽  
Constança Albertí-Casas ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Analysis ◽  
Incidence Rate ◽  
Hazard Analysis ◽  
Competing Risk ◽  
Competing Risk Analysis ◽  
Subdistribution Hazard ◽  
Related Disease ◽  
Asbestos Related Disease

Background. The mortality from all malignant and nonmalignant asbestos-related diseases remains unknown. The authors assessed the incidence and risk factors for all asbestos-related deaths. Methods. The sample included 544 patients from an asbestos-exposed community in the area of Barcelona (Spain), between Jan 1, 1970, and Dec 31, 2006. Competing risk regression through a subdistribution hazard analysis was used to estimate risk factors for the outcomes. Results. Asbestos-related deaths were observed in 167 (30.7%) patients and 57.5% of these deaths were caused by some type of mesothelioma. The incidence rate after diagnosis was 3,600 per 100,000 person-years. In 7.5% of patients death was non-asbestos-related, while pleural and peritoneal mesothelioma were identified in 87 (16.0%) and 18 (3.3%) patients, respectively. Conclusions. Age, sex, household exposure, cumulative nonmalignant asbestos-related disease, and single malignant pathology were identified as risk factors for asbestos-related death. These findings suggest the need to develop a preventive approach to the community and to improve the clinical follow-up process of these patients.

scholarly journals Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Chi-Jung Tai ◽  
Yi-Hsin Yang ◽  
Tzyy-Guey Tseng ◽  
Fang-Rong Chang ◽  
Hui-Chun Wang
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Risk Analysis ◽  
Cancer Prevention ◽  
Cancer Incidence ◽  
Competing Risk ◽  
Research Database ◽  
Competing Risk Analysis ◽  
Β Blocker

Background: Previous studies neglected death as a critical competing risk while estimating the cancer risk for digoxin users. Therefore, the current study aims to assess the effectiveness of digoxin on cancer prevention by competing risk analysis.Methods: We performed a population-based retrospective cohort study using the Taiwan National Health Insurance Research database between 1998 and 2010. After one-to-one propensity score-matching from 36,160 patients with defined criteria, we enrolled 758 patients both in digoxin and β-blocker group for further analysis.Results: The results showed that the digoxin group had higher all-cause mortality than the β-blocker group in the 4- year (10.4 vs. 4.9%) and 8 years (13.6 vs. 7.0%) follow-up. The subdistribution HR of cancer incidence in the digoxin group compared to the β-blocker group was 1.99 (95% confidence interval [CI]: 1.22–3.01) and 1.46 (95% CI: 1.01–2.15) in the 4 years and 8 years follow-up, respectively.Conclusions: The result of our study showed the usage of digoxin has no benefit in cancer prevention compared with β-blocker. The possibility of β-blocker as a new drug candidate for cancer prevention needs further clinical evaluation. The current study also emphasized the necessity of competing risk analysis applying to similar clinical researches.

scholarly journals Extra-Hepatic Comorbidity Burden Significantly Increases 90-day Mortality in Patients with Cirrhosis and High Model for Endstage Liver Disease

2020 ◽  
Author(s):  
Scott Coppel ◽  
Karan Mathur ◽  
Burcin Ekser ◽  
Kavish R Patidar ◽  
Eric Orman ◽  
...  
Keyword(s):  
Liver Disease ◽  
Risk Analysis ◽  
Competing Risk ◽  
Ageing Population ◽  
Competing Risk Analysis ◽  
Comorbidity Burden ◽  
Short Term Mortality ◽  
Cox Proportional Hazard Regression ◽  
Overall Mortality

Abstract Background & aims We examined how extra-hepatic comorbidity burden impacts mortality in patients with cirrhosis referred for liver transplantation (LT). Methods Adults with cirrhosis evaluated for their first LT in 2012 were followed through their clinical course with last follow up in 2019. Extra-hepatic comorbidity burden was measured using the Charlson Comorbidity Index (CCI). The endpoints were 90-day transplant free survival ( Cox-Proportional Hazard regression), and overall mortality (competing risk analysis). Results The study included 340 patients, mean age 56 ± 11, 63% male and MELD-Na 17.2 ± 6.6. The CCI was 0 (no comorbidities) in 44%, 1–2 in 44% and > 2 (highest decile) in 12%, with no differences based on gender but higher CCI in patients with fatty and cryptogenic liver disease. Thirty-three (10%) of 332 patients not receiving LT within 90 days died. Beyond MELD-Na, the CCI was independently associated with 90-day mortality (hazard ratio (HR), 1.32 (95% confidence interval (CI) 1.02–1.72). Ninety-day mortality was specifically increased with higher CCI category and MELD ≥ 18 (12% (CCI = 0), 22% (CCI = 1–2) and 33% (CCI > 2), (p = 0.002)) but not MELD-Na ≤ 17. At last follow-up, 69 patients were alive, 100 underwent LT and 171 died without LT. CCI was associated with increased overall mortality in the competing risk analysis (Sub-HR 1.24, 95%CI 1.1–1.4 ). Conclusions Extra-hepatic comorbidity burden significantly impacts short-term mortality in patients with cirrhosis and high MELD-Na. This has implications in determining urgency of LT and mortality models in cirrhosis and LT waitlisting, especially with an ageing population with increasing prevalence of fatty liver disease.

scholarly journals Association of age and cause-special mortality in patients with stage I/ II colon cancer: A population-based competing risk analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (10) ◽  
pp. e0240715
Author(s):  
Huajun Cai ◽  
Yiyi Zhang ◽  
Xing Liu ◽  
Weizhong Jiang ◽  
Zhifen Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Risk Analysis ◽  
Population Based ◽  
Stage I ◽  
Competing Risk ◽  
Competing Risk Analysis
Sign in / Sign up

Export Citation Format

Share Document